• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?2019冠状病毒病大流行时代的钠-葡萄糖协同转运蛋白2抑制剂：利弊比是否仍然有利？
J Diabetes Sci Technol. 2020 Jul;14(4):745-747. doi: 10.1177/1932296820932155. Epub 2020 Jun 2.
2
Euglycemic Diabetic Ketoacidosis Associated with Empagliflozin Use in the Course of the SARS-Cov-2 Pandemic.在新冠疫情期间使用恩格列净相关的正常血糖性糖尿病酮症酸中毒
J Coll Physicians Surg Pak. 2020 Oct;30(10):110-111. doi: 10.29271/jcpsp.2020.supp2.110.
3
Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic.在新冠疫情期间，对糖尿病患者合理使用钠-葡萄糖共转运蛋白 2 抑制剂。
J Chin Med Assoc. 2020 Sep;83(9):809-811. doi: 10.1097/JCMA.0000000000000354.
4
SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush?用于治疗新型冠状病毒肺炎的钠-葡萄糖协同转运蛋白2抑制剂——是等待发生的奇迹还是又一次的避重就轻？
Prim Care Diabetes. 2020 Oct;14(5):564-565. doi: 10.1016/j.pcd.2020.05.013. Epub 2020 May 28.
5
COVID-19 in diabetic patients: Related risks and specifics of management.COVID-19 与糖尿病：相关风险和管理要点。
Ann Endocrinol (Paris). 2020 Jun;81(2-3):101-109. doi: 10.1016/j.ando.2020.05.001. Epub 2020 May 12.
6
The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的多重效应提示其对新冠病毒疾病（COVID-19）患者可能有益。
Can J Cardiol. 2020 Oct;36(10):1691.e3. doi: 10.1016/j.cjca.2020.07.230. Epub 2020 Jul 24.
7
Sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report.钠-葡萄糖共转运蛋白 2 抑制剂致 2019 冠状病毒病患者血糖正常性糖尿病酮症酸中毒：1 例报告。
J Med Case Rep. 2022 Jan 4;16(1):17. doi: 10.1186/s13256-021-03232-3.
8
Euglycemic diabetic ketoacidosis in a patient with type 1 diabetes and SARS-CoV-2 pneumonia: case-report and review of the literature.1 型糖尿病合并 SARS-CoV-2 肺炎患者的血糖正常糖尿病酮症酸中毒：病例报告及文献复习。
Acta Clin Belg. 2022 Feb;77(1):113-117. doi: 10.1080/17843286.2020.1780390. Epub 2020 Jun 16.
9
Diabetes care during the acute phase of infection in ICU patients with specific attention to COVID-19 outbreak.重症监护病房（ICU）患者感染急性期的糖尿病护理，尤其关注新型冠状病毒肺炎（COVID-19）疫情。
Anaesth Crit Care Pain Med. 2020 Jun;39(3):375-379. doi: 10.1016/j.accpm.2020.06.004. Epub 2020 Jun 17.
10
ISPAD Clinical Practice Consensus Guideline: Diabetic ketoacidosis in the time of COVID-19 and resource-limited settings-role of subcutaneous insulin.ISPAD 临床实践共识指南：COVID-19 大流行期间和资源有限环境中的糖尿病酮症酸中毒——皮下胰岛素的作用。
Pediatr Diabetes. 2020 Dec;21(8):1394-1402. doi: 10.1111/pedi.13118. Epub 2020 Oct 12.

引用本文的文献

1
Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.抗糖尿病治疗对 2 型糖尿病合并 COVID-19 患者临床结局的影响：系统评价和荟萃分析。
Ann Pharmacother. 2023 Jul;57(7):776-786. doi: 10.1177/10600280221133577. Epub 2022 Oct 29.
2
Hospital Diabetes Meeting 2022.2022 年医院糖尿病会议。
J Diabetes Sci Technol. 2022 Sep;16(5):1309-1337. doi: 10.1177/19322968221110878. Epub 2022 Jul 29.
3
Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort.二甲双胍在 2 型糖尿病 COVID-19 患者中的临床结局与高炎症综合征的相关性：基于全港队列的倾向评分分析。
Front Endocrinol (Lausanne). 2022 Mar 7;13:810914. doi: 10.3389/fendo.2022.810914. eCollection 2022.
4
Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care.COVID-19 时期的内分泌学：知识和护理的快速演变。
Medicina (Kaunas). 2021 Aug 6;57(8):805. doi: 10.3390/medicina57080805.
5
COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus.新型冠状病毒肺炎与高血糖及糖尿病的关系
Front Cardiovasc Med. 2021 May 20;8:644095. doi: 10.3389/fcvm.2021.644095. eCollection 2021.
6
Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.使用现有药物保护患有心血管疾病的老年患者免受 COVID-19 并发症的影响。
Eur Geriatr Med. 2021 Aug;12(4):725-739. doi: 10.1007/s41999-021-00504-5. Epub 2021 May 25.
7
Diabetes-related acute metabolic emergencies in COVID-19 patients: a systematic review and meta-analysis.2019冠状病毒病患者中与糖尿病相关的急性代谢急症：一项系统评价和荟萃分析
Diabetol Int. 2021 Mar 23;12(4):445-459. doi: 10.1007/s13340-021-00502-9. eCollection 2021 Oct.
8
Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections.抗糖尿病药物在糖尿病合并冠状病毒感染中的应用前景
Front Pharmacol. 2021 Jan 29;11:592439. doi: 10.3389/fphar.2020.592439. eCollection 2020.
9
Novel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus.糖尿病患者中与2019冠状病毒病相关的新分子证据
J Clin Med. 2020 Dec 7;9(12):3962. doi: 10.3390/jcm9123962.

本文引用的文献

1
Guidelines for the management of diabetes services and patients during the COVID-19 pandemic.COVID-19 大流行期间糖尿病服务和患者管理指南。
Diabet Med. 2020 Jul;37(7):1087-1089. doi: 10.1111/dme.14316. Epub 2020 May 17.
2
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.严重 COVID-19 中的细胞因子释放综合征：白细胞介素-6 受体拮抗剂托珠单抗可能是降低死亡率的关键。
Int J Antimicrob Agents. 2020 May;55(5):105954. doi: 10.1016/j.ijantimicag.2020.105954. Epub 2020 Mar 29.
3
Diabetes is a risk factor for the progression and prognosis of COVID-19.糖尿病是新冠病毒疾病（COVID-19）进展和预后的一个风险因素。
Diabetes Metab Res Rev. 2020 Oct;36(7):e3319. doi: 10.1002/dmrr.3319. Epub 2020 Apr 7.
4
Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study.钠-葡萄糖共转运蛋白 2 抑制剂改善了 1 型糖尿病日本患者的达标时间，而不增加低血糖：一项回顾性、单中心、试点研究。
J Diabetes Investig. 2020 Sep;11(5):1230-1237. doi: 10.1111/jdi.13240. Epub 2020 Mar 27.
5
The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?钠-葡萄糖共转运蛋白 2 抑制剂在住院环境中的应用：是否值得冒险？
J Clin Pharm Ther. 2020 Oct;45(5):883-891. doi: 10.1111/jcpt.13107. Epub 2020 Jan 6.
6
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2019 年更新版：《2018 年美国糖尿病协会（ADA）与欧洲糖尿病研究协会（EASD）关于 2 型糖尿病患者高血糖管理的共识报告》。
Diabetes Care. 2020 Feb;43(2):487-493. doi: 10.2337/dci19-0066. Epub 2019 Dec 19.
7
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.2019年欧洲心脏病学会（ESC）与欧洲糖尿病研究协会（EASD）合作制定的糖尿病、糖尿病前期和心血管疾病指南。
Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486.
8
SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.钠-葡萄糖协同转运蛋白 2 抑制剂会增加社区和住院期间糖尿病酮症酸中毒的发病风险。
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3077-3087. doi: 10.1210/jc.2019-00139.
9
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.达格列净治疗 1 型糖尿病血糖控制不佳患者的疗效和安全性（DEPICT-2 研究）：一项随机对照试验的 24 周结果。
Diabetes Care. 2018 Sep;41(9):1938-1946. doi: 10.2337/dc18-0623. Epub 2018 Jul 19.
10
Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.2型糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂后的糖尿病酮症酸中毒——病例系列
Rev Recent Clin Trials. 2018;13(2):156-160. doi: 10.2174/1574887113666180314101436.

Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?

作者信息

Koufakis Theocharis, Metallidis Symeon, Zebekakis Pantelis, Ajjan Ramzi A, Kotsa Kalliopi

机构信息

Division of Endocrinology and Metabolism and Diabetes Centre, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Greece.

Infectious Diseases Division, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Greece.

出版信息

J Diabetes Sci Technol. 2020 Jul;14(4):745-747. doi: 10.1177/1932296820932155. Epub 2020 Jun 2.

DOI:10.1177/1932296820932155
PMID:32486846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7673172/
Abstract
摘要